Monovalen Phase-1
A Randomized, Double-Blind, and Placebo-Controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS-CoV-2 Variant mRNA Vaccines (ABO1009-DP and ABO-CoV.617.2) in Indonesian Subjects Aged 18 Years and Older Who Have Not Received SARS-CoV-2 Vaccines
Information
This study aims to determine the safety and tolerability profile of ABO 1009-DP and ABO-CoV.617.2 given in 2 doses with an interval of 28 days
Clinical Trial (Vaccine)
COVID-19
Abogen Bioscience
PT. Etana Biotechnologies, Indonesia
Collabolator
Type of Study
Gallery
Head Office Address
Jl. Balai Pustaka Barat 358E
Rawamangun, Pulo Gadung
Jakarta Timur, 13220
Any questions and inquiries, Feel free to contact us:
Contact Us
Corresponding Address
Jalan Pegambiran No. 37 lantai 2,
Rawamangun, Pulo Gadung
Jakarta Timur, 13220